Biocytogen

Biocytogen is a global provider of integrated solutions for next‑generation antibody drug development. Leveraging advanced gene‑editing technologies and a state‑of‑the‑art animal facility, the company offers a seamless platform that spans antibody discovery (including RenMab™ fully human mouse), custom animal model generation, and in‑vivo/in‑vitro preclinical validation. Biocytogen serves more than 70 % of the top 50 pharmaceutical and biotechnology firms, delivering services such as gene targeting, humanized immune‑oncology mouse models, pharmacology, and antibody licensing. By combining cutting‑edge biology with comprehensive CRO capabilities, Biocytogen accelerates the translation of therapeutic antibodies from concept to clinic, helping partners reduce timelines and risk while advancing innovative medicines for patients worldwide.